| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 17 | 2026 | 620 | 2.010 |
Why?
|
| Kidney Diseases | 10 | 2023 | 471 | 2.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 19 | 2026 | 1333 | 1.500 |
Why?
|
| Urethral Obstruction | 8 | 2023 | 55 | 1.330 |
Why?
|
| Breast Neoplasms | 17 | 2026 | 2601 | 1.190 |
Why?
|
| Drug Compounding | 2 | 2025 | 40 | 1.150 |
Why?
|
| Kidney | 18 | 2023 | 1281 | 1.150 |
Why?
|
| Triple Negative Breast Neoplasms | 7 | 2025 | 283 | 0.980 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 4 | 2011 | 18 | 0.970 |
Why?
|
| Nephrosis, Lipoid | 2 | 2023 | 11 | 0.950 |
Why?
|
| Fetal Diseases | 9 | 2023 | 439 | 0.940 |
Why?
|
| Glomerulonephritis | 6 | 2019 | 75 | 0.930 |
Why?
|
| Hypertension | 12 | 2023 | 1349 | 0.920 |
Why?
|
| Silicon Dioxide | 1 | 2025 | 28 | 0.910 |
Why?
|
| Neoadjuvant Therapy | 14 | 2025 | 402 | 0.900 |
Why?
|
| Nephrotic Syndrome | 2 | 2023 | 53 | 0.900 |
Why?
|
| Polymers | 1 | 2025 | 104 | 0.870 |
Why?
|
| Drug Carriers | 1 | 2025 | 117 | 0.860 |
Why?
|
| Nephrology | 2 | 2024 | 159 | 0.850 |
Why?
|
| Urinary Bladder Neck Obstruction | 4 | 2018 | 25 | 0.850 |
Why?
|
| Kidney Failure, Chronic | 6 | 2023 | 938 | 0.830 |
Why?
|
| Interleukin-12 | 6 | 2009 | 124 | 0.730 |
Why?
|
| Biomarkers, Tumor | 11 | 2026 | 1587 | 0.690 |
Why?
|
| Renal Insufficiency | 4 | 2017 | 257 | 0.690 |
Why?
|
| Receptors, Complement | 4 | 2009 | 34 | 0.680 |
Why?
|
| Kidney Transplantation | 4 | 2011 | 558 | 0.650 |
Why?
|
| Urinary Tract | 3 | 2020 | 54 | 0.630 |
Why?
|
| Hypertension, Renal | 4 | 2023 | 30 | 0.630 |
Why?
|
| Stroke | 8 | 2023 | 1060 | 0.590 |
Why?
|
| Humans | 109 | 2026 | 130488 | 0.580 |
Why?
|
| Receptors, Immunologic | 2 | 2014 | 126 | 0.560 |
Why?
|
| Lupus Nephritis | 2 | 2009 | 42 | 0.560 |
Why?
|
| Female | 78 | 2026 | 70404 | 0.540 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2017 | 4 | 0.530 |
Why?
|
| Denys-Drash Syndrome | 1 | 2017 | 2 | 0.530 |
Why?
|
| WT1 Proteins | 1 | 2017 | 23 | 0.530 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2017 | 21 | 0.520 |
Why?
|
| Sodium Chloride | 1 | 2017 | 89 | 0.520 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2017 | 33 | 0.520 |
Why?
|
| Urogenital Abnormalities | 2 | 2016 | 154 | 0.510 |
Why?
|
| Rats, Inbred SHR | 11 | 2023 | 53 | 0.510 |
Why?
|
| Chromosome Mapping | 5 | 2018 | 1046 | 0.510 |
Why?
|
| Hypernatremia | 1 | 2017 | 31 | 0.500 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2020 | 3407 | 0.500 |
Why?
|
| Hyponatremia | 1 | 2017 | 72 | 0.490 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2021 | 849 | 0.490 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2026 | 567 | 0.490 |
Why?
|
| Mice, Inbred MRL lpr | 4 | 2009 | 18 | 0.490 |
Why?
|
| Fluid Therapy | 1 | 2017 | 146 | 0.490 |
Why?
|
| Paclitaxel | 5 | 2025 | 131 | 0.470 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2021 | 501 | 0.460 |
Why?
|
| Proteome | 2 | 2009 | 287 | 0.460 |
Why?
|
| Drug Liberation | 2 | 2025 | 44 | 0.460 |
Why?
|
| Tablets | 2 | 2025 | 36 | 0.460 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 2025 | 51 | 0.460 |
Why?
|
| Coronary Angiography | 1 | 2018 | 452 | 0.450 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2015 | 39 | 0.450 |
Why?
|
| Particle Size | 2 | 2025 | 136 | 0.450 |
Why?
|
| Trastuzumab | 6 | 2026 | 140 | 0.440 |
Why?
|
| Disease Management | 2 | 2018 | 555 | 0.440 |
Why?
|
| Middle Aged | 39 | 2026 | 28383 | 0.430 |
Why?
|
| Graft Survival | 3 | 2011 | 461 | 0.410 |
Why?
|
| Proteomics | 2 | 2009 | 615 | 0.400 |
Why?
|
| Genetic Variation | 4 | 2023 | 1542 | 0.390 |
Why?
|
| Male | 48 | 2026 | 64516 | 0.380 |
Why?
|
| Nephritis, Hereditary | 2 | 2022 | 21 | 0.370 |
Why?
|
| Aged | 29 | 2026 | 20874 | 0.370 |
Why?
|
| Mutation | 6 | 2022 | 6071 | 0.370 |
Why?
|
| Peritoneal Neoplasms | 2 | 2024 | 48 | 0.360 |
Why?
|
| State Medicine | 5 | 2023 | 23 | 0.360 |
Why?
|
| Receptor, Anaphylatoxin C5a | 4 | 2007 | 13 | 0.350 |
Why?
|
| Monocytes | 4 | 2001 | 336 | 0.340 |
Why?
|
| Renal Replacement Therapy | 3 | 2018 | 167 | 0.340 |
Why?
|
| Adult | 32 | 2026 | 31140 | 0.340 |
Why?
|
| Retrospective Studies | 22 | 2026 | 17563 | 0.340 |
Why?
|
| Animals | 29 | 2026 | 33700 | 0.340 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 891 | 0.330 |
Why?
|
| Fluorouracil | 3 | 2026 | 132 | 0.320 |
Why?
|
| Dendritic Cells | 6 | 2009 | 435 | 0.320 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 1 | 2009 | 8 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2025 | 1268 | 0.310 |
Why?
|
| Hemodiafiltration | 2 | 2021 | 17 | 0.310 |
Why?
|
| Kidney Tubules | 2 | 2013 | 76 | 0.300 |
Why?
|
| Ultrasonography, Prenatal | 7 | 2023 | 968 | 0.290 |
Why?
|
| Signal Transduction | 4 | 2024 | 4656 | 0.290 |
Why?
|
| Immunohistochemistry | 5 | 2025 | 1592 | 0.290 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2008 | 3 | 0.290 |
Why?
|
| Kidney Glomerulus | 4 | 2013 | 80 | 0.290 |
Why?
|
| Prospective Studies | 15 | 2025 | 6435 | 0.280 |
Why?
|
| Complement C3a | 2 | 2007 | 18 | 0.280 |
Why?
|
| Proteinuria | 2 | 2006 | 108 | 0.280 |
Why?
|
| Fetus | 3 | 2023 | 567 | 0.280 |
Why?
|
| Albuminuria | 3 | 2014 | 106 | 0.280 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2008 | 60 | 0.280 |
Why?
|
| Sulfhydryl Compounds | 1 | 2008 | 54 | 0.280 |
Why?
|
| Urinary Bladder | 4 | 2023 | 218 | 0.280 |
Why?
|
| Renal Dialysis | 4 | 2023 | 950 | 0.270 |
Why?
|
| Urologic Diseases | 2 | 2019 | 42 | 0.270 |
Why?
|
| Thrombectomy | 2 | 2019 | 121 | 0.270 |
Why?
|
| Rats | 8 | 2023 | 3379 | 0.260 |
Why?
|
| Prognosis | 11 | 2025 | 4867 | 0.260 |
Why?
|
| Haplotypes | 5 | 2019 | 517 | 0.260 |
Why?
|
| Prenatal Care | 2 | 2023 | 344 | 0.260 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2020 | 2823 | 0.260 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 721 | 0.260 |
Why?
|
| Complement Factor H | 2 | 2008 | 24 | 0.260 |
Why?
|
| Brain Ischemia | 3 | 2019 | 268 | 0.260 |
Why?
|
| Plasma Exchange | 2 | 2018 | 86 | 0.260 |
Why?
|
| Complement C4 | 1 | 2007 | 5 | 0.260 |
Why?
|
| Histocompatibility Antigens | 1 | 2007 | 17 | 0.250 |
Why?
|
| Glomerular Filtration Rate | 3 | 2021 | 567 | 0.250 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2024 | 47 | 0.250 |
Why?
|
| Gene Expression Profiling | 5 | 2025 | 1804 | 0.250 |
Why?
|
| Immunosuppressive Agents | 3 | 2014 | 655 | 0.250 |
Why?
|
| Graft Rejection | 1 | 2011 | 558 | 0.250 |
Why?
|
| Child | 22 | 2024 | 26207 | 0.250 |
Why?
|
| Kidney Tubules, Proximal | 2 | 2004 | 74 | 0.250 |
Why?
|
| Ultrasonography, Mammary | 3 | 2021 | 31 | 0.240 |
Why?
|
| Carboplatin | 3 | 2025 | 80 | 0.240 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2019 | 49 | 0.240 |
Why?
|
| Cell Cycle Proteins | 2 | 2021 | 705 | 0.240 |
Why?
|
| RNA, Small Nucleolar | 1 | 2026 | 16 | 0.240 |
Why?
|
| Anxiety | 2 | 2024 | 1006 | 0.240 |
Why?
|
| Receptor, TIE-2 | 1 | 2025 | 13 | 0.230 |
Why?
|
| Excipients | 1 | 2025 | 13 | 0.230 |
Why?
|
| Genome-Wide Association Study | 2 | 2014 | 1826 | 0.230 |
Why?
|
| Tertiary Care Centers | 2 | 2024 | 250 | 0.230 |
Why?
|
| Infant | 16 | 2023 | 13288 | 0.230 |
Why?
|
| Mycophenolic Acid | 2 | 2016 | 54 | 0.230 |
Why?
|
| Solubility | 1 | 2025 | 117 | 0.230 |
Why?
|
| Glomerulonephritis, IGA | 2 | 2018 | 17 | 0.230 |
Why?
|
| Bevacizumab | 1 | 2025 | 59 | 0.230 |
Why?
|
| Porosity | 1 | 2025 | 42 | 0.230 |
Why?
|
| Biological Availability | 1 | 2025 | 136 | 0.230 |
Why?
|
| Solvents | 1 | 2025 | 41 | 0.230 |
Why?
|
| Treatment Outcome | 15 | 2026 | 12877 | 0.220 |
Why?
|
| Cholera Toxin | 2 | 2009 | 44 | 0.220 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2026 | 82 | 0.220 |
Why?
|
| Patients | 1 | 2026 | 122 | 0.220 |
Why?
|
| Cytomegalovirus Infections | 1 | 2007 | 221 | 0.220 |
Why?
|
| Animals, Congenic | 3 | 2020 | 7 | 0.220 |
Why?
|
| Authorship | 1 | 2025 | 30 | 0.220 |
Why?
|
| Drug Hypersensitivity | 1 | 2026 | 99 | 0.210 |
Why?
|
| Immunomodulation | 1 | 2025 | 85 | 0.210 |
Why?
|
| Pregnancy | 10 | 2023 | 7405 | 0.210 |
Why?
|
| Pharmaceutical Preparations | 1 | 2025 | 79 | 0.210 |
Why?
|
| Registries | 4 | 2025 | 1616 | 0.210 |
Why?
|
| Protein Methyltransferases | 1 | 2004 | 9 | 0.210 |
Why?
|
| Perception | 1 | 2026 | 228 | 0.210 |
Why?
|
| Desensitization, Immunologic | 1 | 2026 | 117 | 0.210 |
Why?
|
| Time Factors | 7 | 2021 | 6211 | 0.210 |
Why?
|
| Ribosomes | 1 | 2024 | 124 | 0.210 |
Why?
|
| Blood Pressure | 5 | 2023 | 1344 | 0.200 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2007 | 228 | 0.200 |
Why?
|
| Glomerular Mesangium | 3 | 2003 | 19 | 0.200 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 3028 | 0.200 |
Why?
|
| Hospital Mortality | 3 | 2018 | 1060 | 0.200 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2022 | 154 | 0.200 |
Why?
|
| Survival Rate | 5 | 2025 | 2116 | 0.200 |
Why?
|
| Reperfusion Injury | 1 | 2004 | 108 | 0.190 |
Why?
|
| Risk Factors | 9 | 2021 | 10970 | 0.190 |
Why?
|
| Glomerulonephritis, Membranous | 2 | 2018 | 14 | 0.190 |
Why?
|
| RNA, Messenger | 7 | 2024 | 2553 | 0.190 |
Why?
|
| Albumins | 2 | 2025 | 88 | 0.190 |
Why?
|
| Deoxycytidine | 2 | 2025 | 81 | 0.190 |
Why?
|
| Immunoconjugates | 1 | 2023 | 41 | 0.190 |
Why?
|
| Steroids | 1 | 2023 | 169 | 0.190 |
Why?
|
| Creatinine | 2 | 2021 | 396 | 0.190 |
Why?
|
| Nephritis | 2 | 2023 | 17 | 0.190 |
Why?
|
| Gene Regulatory Networks | 1 | 2025 | 374 | 0.180 |
Why?
|
| Disease Progression | 5 | 2018 | 2196 | 0.180 |
Why?
|
| Cystoscopy | 3 | 2017 | 41 | 0.180 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2024 | 429 | 0.180 |
Why?
|
| Periodicals as Topic | 1 | 2025 | 182 | 0.180 |
Why?
|
| Mice | 13 | 2012 | 18173 | 0.180 |
Why?
|
| Hematuria | 1 | 2022 | 48 | 0.180 |
Why?
|
| Rectal Neoplasms | 1 | 2023 | 78 | 0.180 |
Why?
|
| Transplantation, Homologous | 3 | 2011 | 667 | 0.180 |
Why?
|
| Cognitive Dysfunction | 2 | 2017 | 336 | 0.170 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2001 | 7 | 0.170 |
Why?
|
| BRCA2 Protein | 2 | 2025 | 56 | 0.170 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2017 | 639 | 0.170 |
Why?
|
| Ultrasonography | 2 | 2023 | 946 | 0.170 |
Why?
|
| Biomarkers | 2 | 2018 | 3380 | 0.170 |
Why?
|
| Germany | 4 | 2025 | 58 | 0.170 |
Why?
|
| Pyrimidinones | 1 | 2021 | 62 | 0.170 |
Why?
|
| England | 4 | 2025 | 57 | 0.170 |
Why?
|
| BRCA1 Protein | 2 | 2025 | 79 | 0.170 |
Why?
|
| Cells, Cultured | 7 | 2020 | 2887 | 0.170 |
Why?
|
| Liver Neoplasms | 2 | 2023 | 1366 | 0.170 |
Why?
|
| Receptors, Peptide | 1 | 2001 | 54 | 0.170 |
Why?
|
| Survival Analysis | 5 | 2022 | 1483 | 0.170 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2001 | 32 | 0.170 |
Why?
|
| Education, Medical | 1 | 2025 | 292 | 0.170 |
Why?
|
| Peritoneal Cavity | 1 | 2020 | 18 | 0.170 |
Why?
|
| Watchful Waiting | 1 | 2021 | 73 | 0.160 |
Why?
|
| Cognition | 2 | 2017 | 817 | 0.160 |
Why?
|
| Health Personnel | 1 | 2026 | 548 | 0.160 |
Why?
|
| ras Proteins | 1 | 2021 | 140 | 0.160 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 219 | 0.160 |
Why?
|
| Stromal Interaction Molecule 1 | 1 | 2020 | 8 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2026 | 514 | 0.160 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2000 | 7 | 0.160 |
Why?
|
| Crosses, Genetic | 2 | 2013 | 151 | 0.160 |
Why?
|
| ORAI1 Protein | 1 | 2020 | 6 | 0.160 |
Why?
|
| Lymphocytes | 2 | 2014 | 348 | 0.160 |
Why?
|
| Antigens, CD | 2 | 2000 | 411 | 0.160 |
Why?
|
| Autoantibodies | 2 | 2020 | 436 | 0.160 |
Why?
|
| Child, Preschool | 13 | 2021 | 15010 | 0.160 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 144 | 0.160 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 133 | 0.160 |
Why?
|
| Mice, Knockout | 5 | 2012 | 3814 | 0.150 |
Why?
|
| Perinatal Mortality | 2 | 2019 | 44 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 462 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 5 | 2012 | 4693 | 0.150 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2019 | 44 | 0.150 |
Why?
|
| Foreign-Body Migration | 2 | 2018 | 64 | 0.150 |
Why?
|
| Disease Models, Animal | 7 | 2020 | 4646 | 0.150 |
Why?
|
| Young Adult | 10 | 2025 | 10009 | 0.150 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 710 | 0.150 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 2297 | 0.150 |
Why?
|
| Haemosporida | 1 | 2019 | 1 | 0.150 |
Why?
|
| Parrots | 1 | 2019 | 2 | 0.150 |
Why?
|
| Protozoan Infections, Animal | 1 | 2019 | 4 | 0.150 |
Why?
|
| Prednisone | 1 | 1999 | 237 | 0.150 |
Why?
|
| Bird Diseases | 1 | 2019 | 10 | 0.150 |
Why?
|
| Songbirds | 1 | 2019 | 6 | 0.150 |
Why?
|
| Antineoplastic Agents | 2 | 2026 | 1804 | 0.150 |
Why?
|
| Receptors, Interleukin | 1 | 1999 | 36 | 0.150 |
Why?
|
| Receptors, Cell Surface | 1 | 2001 | 420 | 0.140 |
Why?
|
| Unilateral Breast Neoplasms | 1 | 2018 | 1 | 0.140 |
Why?
|
| Complement C5a | 3 | 2007 | 18 | 0.140 |
Why?
|
| Colectomy | 1 | 2019 | 89 | 0.140 |
Why?
|
| Breath Holding | 1 | 2018 | 6 | 0.140 |
Why?
|
| Pyrazoles | 1 | 2021 | 355 | 0.140 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2018 | 34 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2021 | 3746 | 0.140 |
Why?
|
| Complement C3 | 2 | 2013 | 43 | 0.140 |
Why?
|
| Nervous System Malformations | 1 | 2020 | 136 | 0.140 |
Why?
|
| Germ Cells | 1 | 2019 | 201 | 0.140 |
Why?
|
| Quantitative Trait Loci | 3 | 2018 | 307 | 0.140 |
Why?
|
| Adolescent | 13 | 2025 | 20805 | 0.140 |
Why?
|
| Hypertension, Renovascular | 1 | 2018 | 28 | 0.140 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2019 | 246 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 1070 | 0.140 |
Why?
|
| Extracorporeal Circulation | 1 | 2018 | 48 | 0.140 |
Why?
|
| Receptors, Fc | 1 | 2018 | 29 | 0.140 |
Why?
|
| Infant, Newborn | 8 | 2020 | 8560 | 0.140 |
Why?
|
| Edema | 1 | 2019 | 131 | 0.140 |
Why?
|
| Neoplastic Stem Cells | 1 | 2020 | 330 | 0.140 |
Why?
|
| Chromosomes, Mammalian | 1 | 2018 | 39 | 0.140 |
Why?
|
| Social Support | 1 | 2020 | 363 | 0.140 |
Why?
|
| Urologic Surgical Procedures | 1 | 2018 | 58 | 0.140 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2018 | 28 | 0.140 |
Why?
|
| Recurrence | 3 | 2011 | 1478 | 0.140 |
Why?
|
| Access to Information | 1 | 2018 | 46 | 0.140 |
Why?
|
| Renal Artery Obstruction | 1 | 2018 | 37 | 0.140 |
Why?
|
| Ammonia | 1 | 1998 | 67 | 0.130 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2017 | 6 | 0.130 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 634 | 0.130 |
Why?
|
| Mitochondrial Diseases | 1 | 2019 | 151 | 0.130 |
Why?
|
| Maytansine | 1 | 2017 | 4 | 0.130 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2018 | 107 | 0.130 |
Why?
|
| Hypovolemia | 1 | 2017 | 12 | 0.130 |
Why?
|
| Peptide Fragments | 1 | 2001 | 688 | 0.130 |
Why?
|
| Isotonic Solutions | 1 | 2017 | 38 | 0.130 |
Why?
|
| Catheters, Indwelling | 1 | 2018 | 141 | 0.130 |
Why?
|
| Follow-Up Studies | 6 | 2025 | 5165 | 0.130 |
Why?
|
| Glucocorticoids | 1 | 1999 | 347 | 0.130 |
Why?
|
| Citric Acid | 1 | 2017 | 45 | 0.130 |
Why?
|
| Radiation Injuries | 1 | 2018 | 141 | 0.130 |
Why?
|
| Recovery of Function | 1 | 2019 | 448 | 0.130 |
Why?
|
| Anesthesia, General | 1 | 2018 | 143 | 0.130 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2018 | 73 | 0.130 |
Why?
|
| Lung | 3 | 2015 | 1537 | 0.130 |
Why?
|
| Risk Assessment | 6 | 2020 | 3689 | 0.130 |
Why?
|
| Membrane Proteins | 1 | 2004 | 1588 | 0.120 |
Why?
|
| Peritoneal Dialysis | 1 | 2018 | 133 | 0.120 |
Why?
|
| Aged, 80 and over | 5 | 2026 | 6787 | 0.120 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 1874 | 0.120 |
Why?
|
| Forecasting | 1 | 2018 | 350 | 0.120 |
Why?
|
| Patient Selection | 2 | 2018 | 725 | 0.120 |
Why?
|
| Hematocrit | 2 | 2014 | 104 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 818 | 0.120 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2017 | 78 | 0.120 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 1996 | 16 | 0.120 |
Why?
|
| Liver Failure, Acute | 1 | 2017 | 95 | 0.120 |
Why?
|
| Breast Neoplasms, Male | 1 | 2016 | 18 | 0.120 |
Why?
|
| Coatomer Protein | 1 | 2016 | 28 | 0.120 |
Why?
|
| Organoplatinum Compounds | 2 | 2026 | 34 | 0.120 |
Why?
|
| Endovascular Procedures | 3 | 2019 | 782 | 0.120 |
Why?
|
| Fetal Therapies | 1 | 2017 | 95 | 0.120 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2016 | 78 | 0.120 |
Why?
|
| Biopsy | 3 | 2022 | 1237 | 0.120 |
Why?
|
| Atypical Hemolytic Uremic Syndrome | 1 | 2015 | 13 | 0.120 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 237 | 0.110 |
Why?
|
| Myocardial Ischemia | 1 | 2018 | 308 | 0.110 |
Why?
|
| Prosthesis Failure | 1 | 2016 | 159 | 0.110 |
Why?
|
| Longitudinal Studies | 4 | 2024 | 1484 | 0.110 |
Why?
|
| Quality of Life | 3 | 2021 | 2076 | 0.110 |
Why?
|
| Patient Participation | 1 | 2018 | 251 | 0.110 |
Why?
|
| Interferon-gamma | 5 | 2012 | 547 | 0.110 |
Why?
|
| Electrocoagulation | 1 | 2015 | 31 | 0.110 |
Why?
|
| Urinary Fistula | 1 | 2015 | 14 | 0.110 |
Why?
|
| Lung Diseases | 2 | 2016 | 397 | 0.110 |
Why?
|
| Cyclic AMP | 2 | 2009 | 221 | 0.110 |
Why?
|
| Urethra | 1 | 2015 | 58 | 0.110 |
Why?
|
| Cytokines | 2 | 2000 | 1343 | 0.110 |
Why?
|
| Drainage | 1 | 2016 | 246 | 0.110 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2014 | 2 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 683 | 0.110 |
Why?
|
| Polycystic Kidney, Autosomal Recessive | 1 | 2014 | 10 | 0.110 |
Why?
|
| Pediatrics | 1 | 2024 | 1242 | 0.110 |
Why?
|
| Disease-Free Survival | 3 | 2022 | 903 | 0.100 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 212 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 704 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 393 | 0.100 |
Why?
|
| Gestational Age | 4 | 2020 | 1210 | 0.100 |
Why?
|
| Laparoscopy | 1 | 2019 | 535 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2017 | 385 | 0.100 |
Why?
|
| Heart | 1 | 2018 | 659 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 1288 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2026 | 1374 | 0.100 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 372 | 0.100 |
Why?
|
| Immunoglobulin G | 2 | 2019 | 792 | 0.100 |
Why?
|
| Hemoglobins | 1 | 2014 | 286 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 2 | 2019 | 1692 | 0.100 |
Why?
|
| Preoperative Care | 1 | 2015 | 357 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 776 | 0.100 |
Why?
|
| Alleles | 2 | 2014 | 1674 | 0.100 |
Why?
|
| Species Specificity | 3 | 2014 | 473 | 0.100 |
Why?
|
| Fetoscopy | 1 | 2017 | 459 | 0.100 |
Why?
|
| Complement C7 | 1 | 2012 | 2 | 0.090 |
Why?
|
| Exercise | 2 | 2017 | 862 | 0.090 |
Why?
|
| Anticoagulants | 1 | 2017 | 602 | 0.090 |
Why?
|
| Laser Therapy | 1 | 2015 | 241 | 0.090 |
Why?
|
| Molecular Sequence Data | 3 | 2014 | 3463 | 0.090 |
Why?
|
| Liver Transplantation | 2 | 2018 | 1131 | 0.090 |
Why?
|
| Prenatal Diagnosis | 4 | 2018 | 611 | 0.090 |
Why?
|
| Biopsy, Needle | 2 | 2018 | 204 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 1279 | 0.090 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 422 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2019 | 2463 | 0.090 |
Why?
|
| Fibrosis | 1 | 2013 | 419 | 0.090 |
Why?
|
| CD40 Ligand | 2 | 2002 | 65 | 0.090 |
Why?
|
| Prevalence | 3 | 2016 | 2686 | 0.090 |
Why?
|
| Brain Injuries | 1 | 2016 | 703 | 0.090 |
Why?
|
| Databases as Topic | 1 | 2011 | 73 | 0.080 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1025 | 0.080 |
Why?
|
| Epigenomics | 1 | 2012 | 181 | 0.080 |
Why?
|
| Pandemics | 3 | 2024 | 1156 | 0.080 |
Why?
|
| Virulence Factors, Bordetella | 2 | 2001 | 16 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2025 | 714 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2022 | 387 | 0.080 |
Why?
|
| Tamoxifen | 2 | 2022 | 348 | 0.080 |
Why?
|
| Population Groups | 1 | 2010 | 31 | 0.080 |
Why?
|
| Liver Cirrhosis | 1 | 2017 | 900 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2058 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 2015 | 537 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 564 | 0.080 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2012 | 238 | 0.080 |
Why?
|
| Abnormalities, Multiple | 1 | 2015 | 964 | 0.080 |
Why?
|
| Hepcidins | 1 | 2009 | 26 | 0.080 |
Why?
|
| Receptors, Estrogen | 2 | 2025 | 731 | 0.080 |
Why?
|
| Receptors, Progesterone | 2 | 2025 | 679 | 0.080 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2009 | 37 | 0.080 |
Why?
|
| CD8 Antigens | 1 | 2009 | 39 | 0.070 |
Why?
|
| Interferon Regulatory Factors | 1 | 2009 | 45 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2025 | 4043 | 0.070 |
Why?
|
| Immunoassay | 1 | 2009 | 125 | 0.070 |
Why?
|
| Calcium | 3 | 2020 | 1007 | 0.070 |
Why?
|
| Chemokine CCL2 | 2 | 2000 | 112 | 0.070 |
Why?
|
| Amniotic Fluid | 2 | 2020 | 145 | 0.070 |
Why?
|
| Hepatocyte Nuclear Factor 1 | 1 | 2008 | 2 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2024 | 1216 | 0.070 |
Why?
|
| Mediastinitis | 1 | 2008 | 16 | 0.070 |
Why?
|
| Calcium Signaling | 2 | 2020 | 243 | 0.070 |
Why?
|
| Oligohydramnios | 2 | 2019 | 46 | 0.070 |
Why?
|
| Macrophages | 1 | 2012 | 661 | 0.070 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2012 | 432 | 0.070 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 358 | 0.070 |
Why?
|
| Tissue and Organ Procurement | 1 | 2011 | 255 | 0.070 |
Why?
|
| Cryptococcosis | 1 | 2008 | 38 | 0.070 |
Why?
|
| Genotype | 1 | 2013 | 2588 | 0.070 |
Why?
|
| Gram-Negative Bacteria | 1 | 2007 | 76 | 0.060 |
Why?
|
| Gene Targeting | 1 | 2007 | 169 | 0.060 |
Why?
|
| Base Sequence | 2 | 2014 | 2729 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2022 | 584 | 0.060 |
Why?
|
| United States | 4 | 2024 | 11882 | 0.060 |
Why?
|
| Shock, Septic | 1 | 2007 | 150 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 724 | 0.060 |
Why?
|
| Peptides | 1 | 2009 | 704 | 0.060 |
Why?
|
| Pedigree | 2 | 2022 | 1672 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2026 | 95 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 1607 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2010 | 1242 | 0.060 |
Why?
|
| Linear Models | 2 | 2018 | 686 | 0.060 |
Why?
|
| Anthracyclines | 1 | 2025 | 47 | 0.050 |
Why?
|
| Polysaccharides | 1 | 2026 | 146 | 0.050 |
Why?
|
| Peptide Chain Initiation, Translational | 1 | 2024 | 15 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 776 | 0.050 |
Why?
|
| Mitomycin | 1 | 2024 | 38 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2005 | 331 | 0.050 |
Why?
|
| Expressed Sequence Tags | 1 | 2004 | 77 | 0.050 |
Why?
|
| North America | 1 | 2005 | 256 | 0.050 |
Why?
|
| Hyperthermia, Induced | 1 | 2024 | 51 | 0.050 |
Why?
|
| Complement Activation | 1 | 2004 | 50 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2014 | 2390 | 0.050 |
Why?
|
| Nephrologists | 1 | 2024 | 19 | 0.050 |
Why?
|
| Reference Values | 1 | 2005 | 675 | 0.050 |
Why?
|
| Cell Division | 3 | 2003 | 718 | 0.050 |
Why?
|
| United Kingdom | 1 | 2024 | 254 | 0.050 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2004 | 34 | 0.050 |
Why?
|
| Heart Failure | 1 | 2017 | 2331 | 0.050 |
Why?
|
| Apoptosis | 2 | 2008 | 1830 | 0.050 |
Why?
|
| Self Report | 2 | 2019 | 550 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 436 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2019 | 1230 | 0.050 |
Why?
|
| Urothelium | 1 | 2004 | 55 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2008 | 1364 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2005 | 647 | 0.050 |
Why?
|
| Bacteremia | 1 | 2007 | 430 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2012 | 637 | 0.050 |
Why?
|
| Acute Disease | 3 | 2007 | 1157 | 0.050 |
Why?
|
| Homozygote | 2 | 2019 | 534 | 0.050 |
Why?
|
| Immune Sera | 1 | 2003 | 54 | 0.050 |
Why?
|
| Age of Onset | 1 | 2024 | 594 | 0.050 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2024 | 186 | 0.050 |
Why?
|
| Program Evaluation | 1 | 2025 | 443 | 0.050 |
Why?
|
| Neuropsychological Tests | 2 | 2017 | 953 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2024 | 275 | 0.050 |
Why?
|
| Mobility Limitation | 1 | 2023 | 31 | 0.050 |
Why?
|
| Leishmania tropica | 1 | 2002 | 2 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2023 | 226 | 0.050 |
Why?
|
| Epithelial Cells | 2 | 2004 | 907 | 0.050 |
Why?
|
| Leishmania major | 1 | 2002 | 27 | 0.050 |
Why?
|
| Collagen Type IV | 1 | 2022 | 20 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2015 | 3116 | 0.050 |
Why?
|
| CD40 Antigens | 1 | 2002 | 25 | 0.050 |
Why?
|
| Technology | 1 | 2023 | 68 | 0.050 |
Why?
|
| Interleukin-10 | 2 | 2002 | 187 | 0.050 |
Why?
|
| Leishmania donovani | 1 | 2002 | 26 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2005 | 413 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 1454 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2022 | 100 | 0.040 |
Why?
|
| Hospitals | 1 | 2025 | 437 | 0.040 |
Why?
|
| Autoantigens | 1 | 2022 | 97 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2024 | 571 | 0.040 |
Why?
|
| Depression | 2 | 2024 | 1310 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2001 | 2323 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2009 | 1910 | 0.040 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 2001 | 6 | 0.040 |
Why?
|
| Palliative Care | 1 | 2026 | 448 | 0.040 |
Why?
|
| Genetic Testing | 2 | 2020 | 1105 | 0.040 |
Why?
|
| Receptors, Formyl Peptide | 1 | 2001 | 5 | 0.040 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2001 | 22 | 0.040 |
Why?
|
| Pertussis Toxin | 1 | 2001 | 18 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 993 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2022 | 156 | 0.040 |
Why?
|
| Wales | 1 | 2021 | 7 | 0.040 |
Why?
|
| Hormones | 1 | 2022 | 162 | 0.040 |
Why?
|
| Aromatase Inhibitors | 1 | 2021 | 79 | 0.040 |
Why?
|
| Mental Health | 1 | 2024 | 370 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2001 | 69 | 0.040 |
Why?
|
| Interleukin-4 | 1 | 2001 | 145 | 0.040 |
Why?
|
| Videoconferencing | 1 | 2020 | 21 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2001 | 101 | 0.040 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 48 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 2081 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2008 | 1711 | 0.040 |
Why?
|
| Chemokine CCL8 | 1 | 2000 | 1 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 132 | 0.040 |
Why?
|
| Chemokine CCL7 | 1 | 2000 | 7 | 0.040 |
Why?
|
| Telephone | 1 | 2020 | 110 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 237 | 0.040 |
Why?
|
| Rats, Transgenic | 1 | 2020 | 17 | 0.040 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2020 | 19 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 141 | 0.040 |
Why?
|
| Caribbean Region | 1 | 2019 | 19 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 252 | 0.040 |
Why?
|
| Colon | 1 | 2023 | 363 | 0.040 |
Why?
|
| NFATC Transcription Factors | 1 | 2020 | 39 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 791 | 0.040 |
Why?
|
| Phenotype | 2 | 2019 | 4465 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2014 | 730 | 0.040 |
Why?
|
| RNA | 1 | 2023 | 511 | 0.040 |
Why?
|
| Sex Factors | 2 | 2018 | 1339 | 0.040 |
Why?
|
| Serum Albumin | 1 | 1999 | 101 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2019 | 72 | 0.040 |
Why?
|
| Hepatectomy | 1 | 2020 | 131 | 0.040 |
Why?
|
| RNA Splice Sites | 1 | 2019 | 91 | 0.040 |
Why?
|
| Calcium Channels | 1 | 2020 | 142 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2020 | 112 | 0.040 |
Why?
|
| Receptors, Interleukin-12 | 1 | 1999 | 13 | 0.040 |
Why?
|
| Australasia | 1 | 2019 | 5 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2017 | 3352 | 0.040 |
Why?
|
| Cytochromes b | 1 | 2019 | 5 | 0.040 |
Why?
|
| South America | 1 | 2019 | 45 | 0.040 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2019 | 161 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2019 | 211 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2020 | 176 | 0.040 |
Why?
|
| Patient Preference | 1 | 2020 | 151 | 0.040 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1998 | 40 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 1999 | 93 | 0.040 |
Why?
|
| Amino Acids | 1 | 2021 | 563 | 0.040 |
Why?
|
| Fibrinolysis | 1 | 2018 | 44 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 559 | 0.040 |
Why?
|
| CD3 Complex | 1 | 1999 | 95 | 0.040 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2019 | 104 | 0.040 |
Why?
|
| Muscles | 1 | 2019 | 197 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 311 | 0.040 |
Why?
|
| Radiotherapy, Conformal | 1 | 2018 | 49 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 89 | 0.030 |
Why?
|
| Emergencies | 1 | 2019 | 176 | 0.030 |
Why?
|
| Rehabilitation | 1 | 2018 | 24 | 0.030 |
Why?
|
| Hemofiltration | 1 | 1998 | 11 | 0.030 |
Why?
|
| Th1 Cells | 1 | 1999 | 159 | 0.030 |
Why?
|
| Th2 Cells | 1 | 1999 | 188 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1998 | 411 | 0.030 |
Why?
|
| Europe | 1 | 2019 | 363 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 217 | 0.030 |
Why?
|
| Protozoan Proteins | 1 | 2019 | 127 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 101 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2025 | 2010 | 0.030 |
Why?
|
| Immune System Diseases | 1 | 2018 | 55 | 0.030 |
Why?
|
| Exons | 1 | 2019 | 759 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 1999 | 304 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2020 | 748 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 425 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 1999 | 393 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 320 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 3715 | 0.030 |
Why?
|
| beta 2-Microglobulin | 1 | 2016 | 35 | 0.030 |
Why?
|
| Age Factors | 2 | 2018 | 2827 | 0.030 |
Why?
|
| Critical Illness | 1 | 2021 | 624 | 0.030 |
Why?
|
| PAX2 Transcription Factor | 1 | 2016 | 27 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 2017 | 176 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2016 | 27 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 2016 | 147 | 0.030 |
Why?
|
| Antibodies | 1 | 2018 | 317 | 0.030 |
Why?
|
| Conservative Treatment | 1 | 2017 | 46 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2018 | 137 | 0.030 |
Why?
|
| Chlorides | 1 | 2016 | 97 | 0.030 |
Why?
|
| Phylogeny | 1 | 2019 | 687 | 0.030 |
Why?
|
| Brain Edema | 1 | 2016 | 66 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2016 | 75 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 723 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 135 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1127 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2018 | 484 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 2897 | 0.030 |
Why?
|
| Arthritis | 1 | 2016 | 82 | 0.030 |
Why?
|
| Sodium | 1 | 2016 | 278 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 416 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 308 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 2100 | 0.030 |
Why?
|
| France | 1 | 2015 | 90 | 0.030 |
Why?
|
| Brazil | 1 | 2015 | 116 | 0.030 |
Why?
|
| Mammography | 1 | 2015 | 121 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 272 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1793 | 0.030 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2016 | 225 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2014 | 252 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 373 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2009 | 978 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 711 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2014 | 622 | 0.020 |
Why?
|
| Genomics | 1 | 2021 | 1616 | 0.020 |
Why?
|
| International Cooperation | 1 | 2013 | 161 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 222 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2007 | 766 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2016 | 757 | 0.020 |
Why?
|
| Anemia | 1 | 2014 | 352 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 1207 | 0.020 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2009 | 14 | 0.020 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2009 | 12 | 0.020 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2009 | 38 | 0.020 |
Why?
|
| Inflammation | 1 | 2016 | 1481 | 0.020 |
Why?
|
| Toxoplasmosis | 1 | 2009 | 22 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 891 | 0.020 |
Why?
|
| Hospitalization | 1 | 2018 | 1939 | 0.020 |
Why?
|
| Rats, Inbred WKY | 1 | 2008 | 42 | 0.020 |
Why?
|
| Spleen | 1 | 2009 | 258 | 0.020 |
Why?
|
| Cryptococcus neoformans | 1 | 2008 | 20 | 0.020 |
Why?
|
| Antigens, Fungal | 1 | 2008 | 32 | 0.020 |
Why?
|
| Tomography, Spiral Computed | 1 | 2008 | 14 | 0.020 |
Why?
|
| Animal Feed | 1 | 2008 | 80 | 0.020 |
Why?
|
| Histamine Antagonists | 1 | 2007 | 16 | 0.020 |
Why?
|
| Macrophages, Peritoneal | 1 | 2007 | 37 | 0.020 |
Why?
|
| Platelet Count | 1 | 2007 | 139 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2008 | 101 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2013 | 556 | 0.020 |
Why?
|
| Mast Cells | 1 | 2007 | 67 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2008 | 434 | 0.020 |
Why?
|
| Carotid Artery Diseases | 1 | 2008 | 130 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 277 | 0.020 |
Why?
|
| Family Practice | 1 | 2005 | 84 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2007 | 410 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 2005 | 119 | 0.010 |
Why?
|
| Coronary Disease | 1 | 2008 | 627 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 1391 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2008 | 793 | 0.010 |
Why?
|
| Mice, Congenic | 1 | 2003 | 17 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2003 | 117 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2003 | 92 | 0.010 |
Why?
|
| Endotoxins | 1 | 2003 | 51 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2003 | 164 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 2003 | 112 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2003 | 263 | 0.010 |
Why?
|
| Sheep | 1 | 2003 | 220 | 0.010 |
Why?
|
| Life Style | 1 | 2005 | 446 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2003 | 154 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2003 | 395 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2003 | 585 | 0.010 |
Why?
|
| Weight Loss | 1 | 2005 | 534 | 0.010 |
Why?
|
| Kidney Tubules, Distal | 1 | 2000 | 17 | 0.010 |
Why?
|
| U937 Cells | 1 | 2000 | 23 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2000 | 95 | 0.010 |
Why?
|
| Growth Substances | 1 | 2000 | 99 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2000 | 125 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2000 | 114 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2002 | 450 | 0.010 |
Why?
|
| Ureter | 1 | 2000 | 84 | 0.010 |
Why?
|
| Diet | 1 | 2005 | 1099 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 783 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 2554 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2000 | 1205 | 0.010 |
Why?
|